Horizon Therapeutics plc announced that its Phase II trial evaluating dazodalibep for the treatment of Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity as defined by the European Alliance of Associations for Rheumatology Sjögren’s Syndrome Disease Activity Index score of equal to or higher than 5.
[Horizon Therapeutics plc]
